ChinaBio® Today Blog | Talkmarkets | Page 1
News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

Articles

Latest Posts
1 to 16 of 228 Posts
1 2 3 ... 15
Week In Review: SinoMab To IPO On Hong Kong Exchange
Hong Kong's SinoMab published its prospectus for a Hong Kong IPO to support its antibody program for autoimmune and oncology mAbs.
Week In Review: Jibeier Pharma Files To Raise $100 Million In IPO On New Shanghai STAR Board
Jibeier Pharma, expects to raise $100 million in the offering. The company, plans to use the funds to build a new drug manufacturing facility and R&D center, and to support its R&D of new drugs along with clinical trials.
Week In Review: Tasly Bio Files For $1 Billion Hong Kong IPO
Shanghai Tasly Biopharma, the biologics arm of Tasly Pharma, has filed a prospectus for a Hong Kong IPO expected to raise up to $1 billion.
Week In Review: Immunotherapies Dominate The Week's China Biopharma News
Beijing's BeiGene will receive a $150 million termination fee as Celgene ends its $1.4 billion co-development partnership for BeiGene's PD-1 candidate.
Week In Review: China Biopharma Announces Nearly $3 Billion In Deals
Vivo Capital, a US-China healthcare investor, raised $1.3 billion for its ninth fund, bringing its assets under management to more than $4.3 billion. Hansoh Pharma staged a $1 billion Hong Kong IPO and then rising 37% in its first trading session.
Week In Review: Frontage, A US-China CRO, Stages $205 Million Hong Kong IPO
Frontage Holdings, a US-China CRO, raised $205 million in a Hong Kong IPO at an $820 million valuation and moved 4.5% higher in its first trading session.
Week In Review: Hansoh's Hong Kong IPO To Raise Up To $1 Billion At $10 Billion Valuation
Jiangsu Hansoh Pharma, a generic/novel drug company, will aim to raise up to $1 billion at a $10 billion valuation in its Hong Kong IPO.
Week In Review: WuXi Biologics Signs LOI For $3 Billion Vaccine Contract
WuXi Biologics signed a partnership LOI with an unnamed vaccine company to supply $3 billion of vaccines over 20 years and build a dedicated manufacturing facility
Week In Review: MGI Tech Raises $200 Million To Manufacture Genomic Sequencing Machines
MGI Tech a Shenzhen maker of gene sequencing machines and a subsidiary of genomics company BGI, completed an A funding of more than $200 million.
Week In Review: Gene Editing Scandal; Can China Biopharma Continue To Expand? News On Three China Life Science IPOs
Regulatory changes are speeding drug development timelines for novel imported drugs in China, and VCs raised over $40 billion in new funding last year. Was 2018 as good as it gets, or can the growth in investment activity continue?
Week In Review: Everest In-Licenses An ADC From Immunomedics In $835 Million Agreement, A China Record For A Single Asset
Everest Medicines II of Shanghai, a C-Bridge company, agreed to pay up to a record $835 million in upfront and milestone payments for China rights to an Immunomedics ADC.
Week In Review: Eddingpharm To Pay $375 Million For Two Lilly Antibiotics And A Suzhou Manufacturing Facility
Eddingpharm, a Hong Kong-headquartered China in-licensing company, agreed to pay $375 million to acquire China rights for two off-patent antibiotics from Lilly and the Suzhou factory that makes the antibiotics.
Week In Review: Chi-Med Plans $500 Million Hong Kong IPO
Hutchison China MediTech filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, where it has a market capitalization of over $4 billion. The IPO is expected to raise between $300 million and $500 million.
Week In Review: Hansoh Plans Hong Kong IPO To Raise Up To $1 Billion
Hansoh Pharma, an established drug company, has filed for a Hong Kong IPO, and is rumored to seek between $500 million and $1 billion in new capital. It's a profitable drug company with $1.1 billion in revenue and more than $280 million in profits.
Week In Review: China's Cytovant Signs $1 Billion Deal For Four Medigene I-O Candidates
Cytovant Sciences, a China cell therapy startup, announced a $1 billion partnership with Germany's Medigene to develop four of Medigene's T cell immunotherapy products in China.
Week In Review: CanSino Nears $1 Billion Valuation Following Hong Kong IPO
CanSino Biologics, a Tianjin vaccine company, rose 58% in its first trading day on the Hong Kong Exchange after staging its $161 million IPO. At the IPO price, CanSino was valued at $617 million; its market capitalization is now $968 million.
1 to 16 of 228 Posts
1 2 3 ... 15